SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

TSI Launches Next Generation MacroIMS™ Macroion Spectrometer

Instrumentation Allows for High Resolution Mass and Size Analysis of Proteins, Antibody Aggregates, Viruses/Vaccines/VLPs, Polymers, and Nanoparticles

SHOREVIEW, Minn., March 7, 2014 /PRNewswire/ -- TSI, a worldwide leader in precision measurement instrumentation, announces the launch of its new MacroIMS™ Macroion Spectrometer.

The MacroIMS Macroion Mobility Spectrometer 3982 is a powerful new tool for rapid, high-resolution molecular size and mass analysis of macromolecules. Developed out of core technology for nanoparticle analysis from TSI, the MacroIMS system offers proven utility in a variety of biochemical applications, including analysis of antibody aggregation, lipoproteins, viruses/vaccines/VLPs, polymers, and nanoparticle colloids.

This next-generation instrument boasts a number of new features over previous models, including its ability to perform automated analyses by means of direct connection to LC pumps and auto samplers; soft x-ray ionization eliminating the need for a radioactive source to enable charge neutralization; auto-discovery of components; faster scan times; and chromatography-based software with expanded analytical tools.

TSI Senior Global Product Manager Erik Willis stated, "The power of the MacroIMS Macroion Mobility Spectrometer is its ability to analyze macromolecules and nanoparticles that are too large for mass spectrometry, with a level of accuracy and resolution not achievable with light scatter-based detectors. The MacroIMS Macroion Mobility Spectrometer is a powerful complement to liquid chromatographic, FFF, and AUC separations, and mass spectrometry analyses."

For more information and to send in a sample for analysis, click here or visit, www.tsi.com/MacroIMS.

SOURCE TSI Incorporated

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.